findmyKOL
Clinical trialNCT01851265CompletedPhase 1Interventional

D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid Tumours

SponsorAstraZenecaEnrollment32Solid Tumours
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a 2 part study for patients with solid tumours. The purpose of Part A is to measure the amount of olaparib or its breakdown products in the bloodstream for up to 72 hours after eating 3 different breakfasts (high calorie, regular and none). In Part B Patients can take olaparib capsules daily and study assessments will be recorded for 6 months (minimum). Treatment can continue for as long as the patient is benefitting. Throughout the study patients will be monitored for any side effects.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Belgium
  • Research Site

    Edegem, Belgium

  • Research Site

    Leuven, Belgium

  • Research Site

    Wilrijk, Belgium

Netherlands
  • Research Site

    Amsterdam, Netherlands

  • Research Site

    Maastricht, Netherlands

United Kingdom
  • Research Site

    Glasgow, United Kingdom

  • Research Site

    Manchester, United Kingdom

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Olaparib →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
4 Jul 2013
Primary completion
18 Oct 2013
Completion
6 Jun 2017
Last update posted
28 Aug 2017
Registered enrollment
32
Registry id
NCT01851265

Cross-registrations

EU-CTR / CTIS (EudraCT)2013-001255-13
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.